Clinical Trial Update: First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor [Phase 1]

View source ↗

Summary

This update reports the completion of a first-in-man Phase 1 study evaluating SAR566658 in CA6-positive, refractory solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• SAR566658

Snippet

Sponsor: Sanofi | Conditions: Neoplasm Malignant | Phase 1 | Status: COMPLETED